Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134119 | 0.85 | TLR7 (0.45) | TLR7 | |
| SCHEMBL4223137 | 0.83 | TLR7 (0.48) | TLR7 | |
| SCHEMBL4135314 | 0.83 | TLR7 (0.46) | TLR7 | |
| SCHEMBL4215187 | 0.83 | TLR7 (0.48) | TLR7 | |
| SCHEMBL4227687 | 0.83 | TLR7 (0.48) | TLR7 | |
| SCHEMBL4224695 | 0.83 | TLR7 (0.48) | TLR7 | |
| SCHEMBL4223818 | 0.83 | TLR7 (0.48) | TLR7 | |
| SCHEMBL4223319 | 0.82 | TLR7 (0.49) | TLR7 | |
| SCHEMBL4129067 | 0.82 | TLR7 (0.49) | TLR7 | |
| SCHEMBL4216266 | 0.81 | TLR7 (0.47) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | XDH, ADORA1, NUDT1 | HRH3 162/4885TLR7 396/4885KCNH2 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.